Search clinical trials for: AZD7594 and abediterol

Total 269905 results

AstraZeneca
Parexel

Completed

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma

Asthma

Germany
AstraZeneca
Parexel

Terminated

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Asthma

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Asthma

Germany
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids

Asthma

Germany
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Steatohepatitis

United States, Puerto Rico
LYZZ Alpha Holding Ltd
Tigermed Consulting Co., Ltd

Completed

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Non Small Cell Lung Cancer

China
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca
Parexel

Recruiting

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

Healthy Subjects | Crohns Disease

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Pharmacokinetics | Healthy Participants | Tolerability | Safety

United States
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
AstraZeneca

Completed

To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Alzheimer's Disease

United States
AstraZeneca

Completed

An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

Maximum Diagnostic Mass of [18Fluor]AZD4694

Sweden
Arrow Therapeutics

Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Healthy

United Kingdom
AstraZeneca

Completed

An Open Label Prostate Cancer Study in Japanese Patients

Prostate Cancer

Japan
AstraZeneca

Completed

Open Label Prostate Cancer Study

Prostate Cancer

United Kingdom, Netherlands, United States
Arrow Therapeutics

Completed

Pharmacokinetics of AZD7295 Capsules

Healthy

United Kingdom
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
AstraZeneca

Completed

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, Nonalcoholic

United States
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Healthy Subjects

Japan
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid (PET)

Alzheimer's Disease

Sweden
AstraZeneca

Recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Cancer

United Kingdom
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
Jeeyun Lee

Recruiting

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Stomach Cancer, Adenocarcinoma

Korea, Republic of
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
AstraZeneca

Completed

To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients

Healthy Subjects | COPD

United Kingdom
AstraZeneca

Completed

Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge

LPS Challenge, Neutrophils

United Kingdom
AstraZeneca

Completed

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
AstraZeneca
Parexel

Completed

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Solid Tumors

United States
National Jewish Health

Completed

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

Corticosteroid Resistant (CR) Asthmatics

United States
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine

3

Subscribe